In RA, “strong bones” can give false reassurance. Pts with higher baseline BMD had faster bone loss, often tied to GC use and less osteoporosis treatment. Undermanagement, not biology, may drive decline. @RheumNow #ACR25 Abstract#2244 https://t.co/N421ESAUy9

• https://x.com/JihaRheum/status/1983230532231332183/photo/1

After melanoma, should RA patients stop DMARDs? These VA data (n=644) showed no mortality signal, and trending to survival benefit with b/tsDMARDs Provisos over methotrexate, invasive disease etc, but don’t hold off treating the RA because of melanoma #ACR25 ABST2237 @RheumNow https://t.co/l9n1V6YVln

• https://x.com/drdavidliew/status/1983229116469162290/photo/1

#ACR25 Abstr#LB11 2025 belongs to Sjogren! In patients with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met primary endpoint; change in ESSDAI vs PBO. ESSPRI improved too! Wow! That PBO response was a flat line! Will need Global study @RheumNow #ACRBest https://t.co/LXxpBZPCtF

• https://x.com/Yuz6Yusof/status/1983228550187528205/photo/1

#IL2 #Rx in active #SLE? Maybe 🤔 IL2 is tricky - low dose May help #SLE but too much of a good thing may have a neg impact. RCT of IL2i in #SLE gave a good dose response and improved TRegs. #ACRBest #ACR25 @RheumNow @ACRheum #LB01 https://t.co/F61qz5x5We

• https://x.com/Janetbirdope/status/1983227740267422026/photo/1
• https://x.com/Janetbirdope/status/1983227740267422026/photo/1

Can a Fitbit track RA? This Japanese clinic is using Fitbit data and have seen it correlate with CDAI across their RA clinic. Maybe instead of asking about our patients mobility and sleep, we should be measuring it? #ACR25 ABST2253 @RheumNow https://t.co/rg2SKgn7K2

• https://x.com/drdavidliew/status/1983227402605211728/photo/1

#1751 In early RA, higher disease activity, inflammation & older age linked to more ILD changes on machine-learning chest CT. Even subtle QCT abnormalities correlated with reduced lung function pointing to early inflammatory pathways in RA-ILD. @RheumNow #ACR25

Are the clues of RA there in the EMR, before the diagnosis is made? Jina off-the-shelf AI with subsequent retraining found the digital fingerprint of RA in @MayoClinic medical notes, years before formal diagnosis. The clues are there #ACR25 ABST2260 @MyasoedovaElena @RheumNow https://t.co/onGlKUmefd

• https://x.com/drdavidliew/status/1983225667119419748/photo/1

Adverse events from avacopan the WHO pharmacovigilence database (VigiBase) Not a lot new - infections happen, hepatic events happen but seem to be somewhat rare Pharmacovigilence is hard; most events go unreported & we often have the classic "denominator problem" (ie we saw https://t.co/28tYkXv0Lz

• https://x.com/EBRheum/status/1983225627403563379/photo/1

Eder et al. Deucravacitinib in PsA from POETYK-PsA stuides. Male and female patients had similar response rates at week 16. ACR 20 57% vs 51%, ACR50 27% vs 27%, ACR70 12% vs 10%, MDA 24% vs 20%. @RheumNow #ACR25 Abstr#2356 https://t.co/bImzTA7uUC

• https://x.com/RichardPAConway/status/1983225499255185474/photo/1

In a 4-year study of 85 SpA patients, ChatGPT-4o matched SPSS in analyzing NLR/PLR trends. Outputs were identical, but ChatGPT offered faster interpretation and clinical context, highlighting AI’s potential to streamline early-stage research. Abstract#2354 @RheumNow #ACR25 https://t.co/W3pPQijPBD

• https://x.com/synovialjoints/status/1983224744808984704/photo/1

In the CLOSE-UP study of UPA in RA - 61% in remission with responses sustained to 24 mo - Benefit consistent irrespective of prior DMARD use - No new safety signals @RheumNow #ACR25 Abstract#2281

Infection vs steroid sparing in PMR/GCA/AAV studies with steroid-sparing Rx GiACTA (1, top right) aside, - low infection rates - the more steroid saved, the less the infection risk Infection risk in vasculitis is driven by steroid, not DMARD #ACR25 ABST2526 @RheumNow https://t.co/UprbxUQyQC

• https://x.com/drdavidliew/status/1983221326518026404/photo/1

#ACR25 Abstr#LB10 Promising 4-Year data of Deucravacitinib in blinded phase 2 RCT +LTE study showed efficacy inc. LLDAS and CLASI-50 response were maintained/improved over time in #SLE No concerning safety signal. Looking forward to Phase 3 results next year @RheumNow https://t.co/fZv82zJ6Q4

• https://x.com/Yuz6Yusof/status/1983220916264771657/photo/1

Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. Progressive ILD in 23%. Similar to the numbers progressing on baricitinib by same group. Previous MTX treatment appears to REDUCE risk (OR 0.45). Disease activity increases risk (OR 1.29). @RheumNow #ACR25 Abstr#2265 https://t.co/0tl0kGgm5p

• https://x.com/RichardPAConway/status/1983218705136800239/photo/1

#ACR25 How hard will you go & at what cost? A study in China using CD20/BCMA Bispecific autologous CAR-T showed profound depletion, normalisation of abs and good response in #SLE (10/11 had LN). But 2 had G3 infections & cytopenia. Presenters said some had IVIG @RheumNow #ACRBest https://t.co/TF0wpib5rr

• https://x.com/Yuz6Yusof/status/1983218032924119234/photo/1
• https://x.com/Yuz6Yusof/status/1983218032924119234/photo/1